Cytek Biosciences (CTKB) Competitors

Cytek Biosciences (NASDAQ:CTKB) and Transcat (NASDAQ:TRNS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends.

Does the MarketBeat Community believe in CTKB or TRNS?

Transcat received 190 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 66.88% of users gave Transcat an outperform vote while only 45.45% of users gave Cytek Biosciences an outperform vote.

Company	Underperform	Outperform
Cytek Biosciences	Outperform Votes 20 45.45%	Underperform Votes 24 54.55%
Transcat	Outperform Votes 210 66.88%	Underperform Votes 104 33.12%

Do insiders and institutionals hold more shares of CTKB or TRNS?

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 9.6% of Cytek Biosciences shares are owned by company insiders. Comparatively, 2.3% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Do analysts recommend CTKB or TRNS?

Cytek Biosciences presently has a consensus price target of $9.25, indicating a potential upside of 46.36%. Transcat has a consensus price target of $130.25, indicating a potential upside of 23.17%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cytek Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Transcat	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Is CTKB or TRNS more profitable?

Transcat has a net margin of 6.63% compared to Cytek Biosciences' net margin of -5.05%. Transcat's return on equity of 7.36% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-5.05%	-2.58%	-2.05%
Transcat	6.63%	7.36%	5.90%

Which has better valuation & earnings, CTKB or TRNS?

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.21M	4.05	-$12.15M	-$0.08	-79.00
Transcat	$270.61M	3.59	$13.65M	$1.98	53.41

Which has more volatility & risk, CTKB or TRNS?

Cytek Biosciences has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Transcat has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Does the media prefer CTKB or TRNS?

In the previous week, Transcat had 8 more articles in the media than Cytek Biosciences. MarketBeat recorded 10 mentions for Transcat and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.38 beat Transcat's score of -0.39 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Transcat	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Transcat beats Cytek Biosciences on 12 of the 18 factors compared between the two stocks.